Vaxart Amends 8-K for Officer/Director Changes, Compensation

TL;DR

**Vaxart just corrected an earlier filing about executive changes or pay, so keep an eye on leadership details.**

AI Summary

Vaxart, Inc. filed an amended 8-K/A on February 2, 2024, to correct a previous filing from January 15, 2024. This amendment specifically addresses Item 5.02, which covers changes in directors or officers and their compensation arrangements, and Item 9.01 regarding financial statements and exhibits. While the filing doesn't detail the specific changes, it indicates a correction was needed for information related to executive compensation or board composition. This matters to investors because accurate and timely disclosure of executive changes and compensation is crucial for assessing leadership stability and potential future performance, directly impacting investor confidence in Vaxart's governance.

Why It Matters

This amendment signals a correction to previously reported information about Vaxart's leadership or executive pay, which is vital for investors to have accurate data when evaluating the company's management and financial health.

Risk Assessment

Risk Level: low — An 8-K/A for an amendment is generally a low risk event, as it typically corrects minor errors or provides additional detail rather than signaling a major negative event.

Analyst Insight

A smart investor would review the original 8-K from January 15, 2024, and then look for the specific details of the amendment to understand what changes were made regarding executive compensation or officer/director appointments, as these can impact governance and future performance.

Key Players & Entities

• Vaxart, Inc. (company) — the registrant filing the 8-K/A
• January 15, 2024 (date) — date of the earliest event reported in the original 8-K
• February 2, 2024 (date) — date the 8-K/A was filed
• Item 5.02 (other) — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
• Item 9.01 (other) — Financial Statements and Exhibits

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
• $5,000 — ayout date, (iv) reimbursement of up to $5,000 in attorney fees incurred in negotiatin

Filing Documents

• vxrt20240202_8ka.htm (8-K/A) — 29KB
• ex_622122.htm (EX-10.1) — 101KB
• 0001437749-24-002971.txt ( ) — 288KB
• vxrt-20240115.xsd (EX-101.SCH) — 3KB
• vxrt-20240115_def.xml (EX-101.DEF) — 12KB
• vxrt-20240115_lab.xml (EX-101.LAB) — 15KB
• vxrt-20240115_pre.xml (EX-101.PRE) — 12KB
• vxrt20240202_8ka_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 31, 2024, the Company entered into a Separation Agreement with Mr. Floroiu (the "Separation Agreement"). Pursuant to the Separation Agreement, the Company agreed to provide Mr. Floroiu with the following payments and benefits (the "Separation Benefits"): (i) continued base salary for 12 months, (ii) subsidized health insurance premiums for 12 months, (iii) the 2023 bonus, if any, to which he would have been entitled to receive had he remained employed by the Company through the payout date, (iv) reimbursement of up to $5,000 in attorney fees incurred in negotiating the agreement, (v) accelerated vesting of his equity awards that would have vested through September 30, 2024, and (vi) up to two years to exercise his vested stock options after termination of employment. In exchange for these benefits, Mr. Floroiu has signed a release of claims in favor of the Company and agreed to certain confidentiality, non-competition, non-solicitation of personnel and customers, non-disparagement and cooperation covenants. The Separation Benefits are conditioned upon Mr. Floroiu's non-revocation of the release of claims and his compliance with the restrictive covenants. The foregoing description of the Separation Agreement is qualified in its entirety by reference to the full text of the document, which is attached as Exhibit 10.1 to this Amendment and is hereby incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Separation Agreement, dated January 31, 2024, by and between Vaxart, Inc. and Andrei Floroiu. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vaxart, Inc. Dated: February 2, 2024 By: /s/ MICHAEL J. FINNEY Michael J. Finney, Ph.D. Interim Chief Executive Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR